Search for European Projects

Over 40 European Projects Found

Searched on 125080 European Projects

 FINISHED 

AnTBiotic – progressing TB drug candidates to clinical proof of concept (anTBiotic)

Start date: Jan 1, 2017, End date: Dec 31, 2021,

Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeli ...
Read Project

 5

 FINISHED 

Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)

Start date: Jan 1, 2015, End date: Dec 31, 2021,

Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Read Project

 44

 FINISHED 

Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)

Start date: Jun 1, 2015, End date: Nov 30, 2020,

The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Read Project

 25

 FINISHED 

Doctoral Industrial School on Human Skin models for Staphylococcal infections (DISSection)

Start date: Nov 1, 2016, End date: Oct 31, 2020,

Staphylococcus aureus (S. aureus) is a major human pathogen and cutaneous infections are among the leading cause of emergency department visits. Unfortunately, S. aureus vaccine development is hindered by the lack of known correlates of protection. Three dimensional organotypic human skin models may represent a valid alternative to animal infection model.Indeed, S. aureus expresses several human-s ...
Read Project

 2

 FINISHED 

Doctoral Industrial School for Vaccine Design through Structural Mass Spectrometry (VADEMA)

Start date: Nov 1, 2016, End date: Oct 31, 2020,

Vaccines discovered from empirical approaches and consisting in killed, live-attenuated microorganisms or purified components have led to the successful control of many devastating diseases. Several novel technologies, such as recombinant DNA technology, glycoconjugation, reverse vaccinology have opened the possibility of designing vaccines previously considered impossible to make. Despite decades ...
Read Project

 2

 FINISHED 

Leveraging Pharmaceutical Sciences and Structural Biology Training to develop 21st Century Vaccines (PHA-ST-TRAIN-VAC)

Start date: Jun 1, 2016, End date: May 31, 2020,

Immunisation is one of the most cost-effective and proven tools to control and eliminate infectious diseases, saving millions of lives each year, yet key challenges remain in order to guarantee the future health of the expanding and ageing global population. For example, effective vaccines are still required for Respiratory Syncytial Virus (RSV) and Group B Streptococcus (GBS), both of which cause ...
Read Project

 2

 FINISHED 

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes (DiViNe)

Start date: Mar 1, 2015, End date: Feb 29, 2020,

In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations ...
Read Project

 6

 FINISHED 

Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)

Start date: Mar 1, 2015, End date: Feb 29, 2020,

Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Read Project

 26

 FINISHED 

Combatting Bacterial Resistance in Europe - Carbapenem Resistance (COMBACTE-CARE)

Start date: Mar 1, 2015, End date: Feb 28, 2020,

Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. Although focused strategies have beneficially influenced infection rates due to methicillin resistant Staphylococcus aureus (M ...
Read Project

 23

 FINISHED 

European Gram Negative Antibacterial Engine (ENABLE)

Start date: Feb 1, 2014, End date: Jan 31, 2020,

The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future medical advances are negated. Resistant bacteria dramatically reduce the possibilities of treating infections effectively, a ...
Read Project

 42

 FINISHED 

INternational Smart Collaborative Open-access hybrid Printed Electronics pilot line (InSCOPE)

Start date: Jan 1, 2017, End date: Dec 31, 2019,

The InSCOPE project will set-up an open access pilot line service for Hybrid TOLAE (H-TOLAE) technologies capable of sampling products at TRL6-7. It positions itself in between R&D and industry and deploys a service for validating potential H-TOLAE products. Manufacturing progresses beyond R&D level (TRL5 towards 6) by improving processes, functionality and reliability allowing sampling at high qu ...
Read Project

 14

 FINISHED 

Combatting Bacterial Resistance in Europe (COMBACTE-NET)

Start date: Jan 1, 2013, End date: Dec 31, 2019,

The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are aro ...
Read Project

 38

 FINISHED 

A training network for the rational design of the next generation of well-defined glycoconjugate vaccines (GLYCOVAX)

Start date: Nov 1, 2015, End date: Oct 31, 2019,

GLYCOVAX is a network for the education of promising young scientists who will learn how to rationally design a next generation of well-defined and innovative glycoconjugate vaccines to improve current preventive therapies and to tackle unmet medical needs. Glycoconjugate vaccines represent the key for success of vaccination in children. The covalent linkage to proteins renders carbohydrates able ...
Read Project

 12

 FINISHED 

Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)

Start date: Jul 1, 2014, End date: Jun 30, 2019,

The current healthcare systems are built around the traditional paradigm of patients suffering from a single acute illness. They are therefore largely unprepared to face the increasing demands for health services arising from the expansion of an older population with specific medical needs related to multiple chronic disorders. As a consequence, the medical conditions of a large and growing seg ...
Read Project

 27

 FINISHED 

New generation of carbohydrate-based vaccines via rational understanding of their immunological mechanism (NEWCARBOVAX)

Start date: Jun 13, 2016, End date: Jun 12, 2019,

Glycoconjugate vaccines have provided enormous health benefits globally, but they have been less successful in some populations at high risk for developing disease. They are composed by a sugar antigen covalently linked to a carrier protein. The traditional hypothesis of immune activation by glycoconjugate vaccines suggests that only peptides generated from glycoconjugate processing can be present ...
Read Project

 1

 FINISHED 

"Proposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes" (EXALT)

Start date: Feb 1, 2014, End date: Jan 31, 2019,

"Type-1 diabetes (T1D) is an autoimmune disease in which pancreatic β-cells are gradually destroyed by autoreactive T-cells recognising autoantigens (Auto-Ag) such as GAD65 and insulin. ImCyse, a small SME, has developed a new technology based on short synthetic peptides flanked with a thioredox motif, which silence the pathogenic immune response against several auto-Ag through activation of one a ...
Read Project

 7

 FINISHED 

The next generation epigenetic medicine for inflammation (EPIMAC)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

...asingly clear that deregulated epigenetic processes are associated with the aberrant inflammatory response seen in IBD. Recent reports suggest that inhibitors of epigenetic modifications developed by GlaxoSmithKline (GSK), such as histone deacetylase (HDAC) inhibitors, bear potential in treating inflammatory states (Nicodeme et al, Nature 2010; Kruidenier et al, Nature 2012). The EPIMAC consortium ...
Read Project

 2

 FINISHED 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Read Project

 29

 FINISHED 

Robust and affordable process control technologies for improving standards and optimising industrial operations (ProPAT)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

The Process Industries require a high degree of automation, monitoring, and advanced simulation and control for their often complex manufacturing processes and operations. Emphasis is on continuous or batch production, mixing, reaction and separation of materials of higher value. Indeed, increased globalisation and competition are drivers for process analytical technologies (PAT) that enable seaml ...
Read Project

 18

 FINISHED 

TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Read Project

 49

 FINISHED 

Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)

Start date: Oct 1, 2013, End date: Sep 30, 2018,

Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Read Project

 30

 FINISHED 

Graphene-based disruptive technologies (GrapheneCore1)

Start date: Apr 1, 2016, End date: Mar 31, 2018,

This project is the second in the series of EC-financed parts of the Graphene Flagship. The Graphene Flagship is a 10 year research and innovation endeavour with a total project cost of 1,000,000,000 euros, funded jointly by the European Commission and member states and associated countries. The first part of the Flagship was a 30-month Collaborative Project, Coordination and Support Action (CP-CS ...
Read Project

 158

 FINISHED 

Improving Prostate Cancer Outcome with Vectored Vaccines (IMPROVE)

Start date: Apr 1, 2014, End date: Mar 31, 2018,

A successful vaccine against cancer is most likely to work through the induction of potent CD8+ T cells that can successfully kill tumour cells. But achieving this has proved difficult and only low level responses are induced by current vaccine approaches. Nonetheless, two therapeutic immunisation strategies have shown partial success in targeting prostate cancer, and one recently reached licensur ...
Read Project

 5

 FINISHED 

A multidisciplinary Doctoral Industrial School on novel preventive strategies against E. Coli infections (DISCO)

Start date: Apr 1, 2014, End date: Mar 31, 2018,

The doctoral school proposed in DISCo originates from the common interest of Novartis Vaccines (NVD) and the French National Institute of Agronomical Research (INRA) in preventing E. coli infections. Both Institutes have a strong background in microbial pathogenesis, supported by a number of ongoing research programmes aimed at combating human infectious diseases. In particular, NVD, by using a hi ...
Read Project

 2

 FINISHED 

Nanotherapeutics for antibiotic resistant emerging bacterial pathogens (NAREB)

Start date: Feb 1, 2014, End date: Jan 31, 2018,

Increase in antibiotic resistance is a global concern worldwide. The project NAREB's main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the therapy of multi-drug resistant (MDR) tuberculosis (TB) and MRSA infections in European MDR patients.NAREB will address the problem of drug bioavailability inside the infected macrophages, transport ...
Read Project

 16

 FINISHED 

Hit to lead optimisation of novel anti-TB scaffolds through an academic-industrial partnership (Coopera-TB)

Start date: Feb 1, 2014, End date: Jan 31, 2018,

We propose a PhD programme for 4 Early-Stage Researchers (ESR) in tuberculosis (TB) drug discovery. Often associated with poverty, TB is rampant in many parts of Africa and Asia but has now also returned to developed nations. Growing resistance against currently used antibiotics is one of the most pressing problems of the global TB epidemic. Treating TB infections requires a drug cocktail given fo ...
Read Project

 2

 FINISHED 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Start date: Sep 1, 2011, End date: Dec 31, 2017,

The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Read Project

 26

 FINISHED 

European Medical Information Framework (EMIF)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Read Project

 64

 FINISHED 

Molecular basis of the outer membrane permeability (TRANSLOCATION)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallizat ...
Read Project

 28

 FINISHED 

The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease (DAVIAD)

Start date: Dec 1, 2013, End date: Nov 30, 2017,

This aim of the DAVIAD proposal is to develop a therapeutic vaccine for Graves’ disease (GD) that has a better safety and efficacy profile than current treatments. There is a high level of unmet need in the treatment of Graves’ disease especially in patients with Graves orbitopathy and children and adolescents (who generally suffer from the most chronic form of the disease). Autoimmune diseases ar ...
Read Project

 5

 FINISHED 

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Read Project

 22

 FINISHED 

Kinetics for Drug Discovery (K4DD) (K4DD)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Read Project

 21

 FINISHED 

Model-based preclinical development of anti-tuberculosis drug combinations (PREDICT-TB)

Start date: May 1, 2012, End date: Oct 30, 2017,

Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical sy ...
Read Project

 23

 FINISHED 

Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine (EbolaVac)

Start date: Oct 7, 2014, End date: Oct 6, 2017,

The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organization (WHO) reports the total number of cases in the current outbreak of Ebola virus disease (EVD) in West Africa at 7470, with 3431 deaths. The US Centers for Disease Control and Prevention states that the number of cases is currently doubling every 20 days and e ...
Read Project

 5

 FINISHED 

Advanced Immunization Technologies (ADITEC)

Start date: Oct 1, 2011, End date: Sep 30, 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Read Project

 53

 FINISHED 

Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Read Project

 17

 FINISHED 

Oral biopharmaceutics tools (ORBITO)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Read Project

 28

 FINISHED 

DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE (DRIVE-AB)

Start date: Oct 1, 2014, End date: Sep 30, 2017,

Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mechanisms of action is scientifically complex, the chief challenge is diminishing incentives. Pre-market regulatory requirements ...
Read Project

 27

 FINISHED 

Recognising Adverse Drug Reactions (WEB-RADR)

Start date: Sep 1, 2014, End date: Aug 31, 2017,

WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Read Project

 20

 FINISHED 

Structural Vaccinology in the design of bionanoparticles with multi-copy antigen display for vaccines with enhanced efficacy (SVNanoVax)

Start date: Jun 15, 2015, End date: Jun 14, 2017,

Vaccines are the most effective way to protect humans from infectious disease and may save over 2 million lives per year (Delany, 2013). A key issue for future vaccines is how to improve immunogenicity without reducing safety (Bachmann, 2010). Another challenge is that high antigen sequence variability enables pathogens to escape the host response. To overcome these challenges, this proposal combi ...
Read Project

 1